InstalabLoading...
InstalabLoading...
A measure of how close your urine is to forming calcium phosphate crystals, revealing your risk of one of the most pH-sensitive types of kidney stones.
If you have ever passed a kidney stone or worry about forming one, calcium phosphate supersaturation (CaP SS) tells you something no other single number can: how close your urine is to the tipping point where calcium phosphate crystals begin to form. A value above 1 means the calcium and phosphate dissolved in your urine exceed what the liquid can hold in solution. Think of it like a glass of water with too much sugar stirred in. Eventually, the excess settles out as solid crystals.
This matters because calcium phosphate stones account for 10 to 15% of all kidney stones and 15 to 20% of calcium stones specifically, and their share has been growing over time. Calcium phosphate also shows up as a minor ingredient in up to 30% of calcium oxalate stones. Even if your last stone was mostly calcium oxalate, calcium phosphate may have been the initial seed it grew on.
What makes this biomarker especially useful is its tight relationship with urine pH. Unlike calcium oxalate supersaturation, which does not change much with pH, calcium phosphate supersaturation climbs rapidly as urine pH rises from 6 to 7. That single variable, how alkaline your urine is, can be the difference between a safe margin and active crystal formation.
Five factors determine your calcium phosphate supersaturation: calcium concentration, phosphate concentration, citrate concentration, urine volume, and pH. Of these, pH deserves special attention. When your urine becomes more alkaline, phosphate shifts into forms that bind calcium more aggressively, pushing supersaturation higher. This is why conditions that prevent your kidneys from acidifying urine are so strongly linked to calcium phosphate stones.
Citrate acts as a natural inhibitor. It binds calcium in urine, keeping it from pairing with phosphate. Low citrate (a condition called hypocitraturia) removes that protective brake. High calcium excretion (hypercalciuria) floods the system with raw material. And low urine volume concentrates everything, making crystal formation more likely.
The interplay of these factors explains why people in the highest supersaturation ranges are substantially more likely to be stone formers. In large cohort studies, those with the highest calcium phosphate supersaturation had roughly 2 to 4 times the odds of being a stone former compared to those with the lowest values (odds ratios of 1.86 to 4.37).
Your urine pH is not always under your dietary control. Several medical conditions and medications can lock it in an alkaline range, creating a persistent stone-forming environment. Understanding these categories helps you figure out whether your elevated supersaturation has a correctable cause.
Kidney acidification defects: The most important is distal renal tubular acidosis (dRTA), a condition where your kidneys lose the ability to secrete acid into the urine. The hallmark triad is alkaline urine pH above 6.5, low citrate, and high calcium excretion. dRTA was found in 32% of brushite stone formers and 42% of hydroxyapatite stone formers, compared to only 3% of calcium oxalate stone formers. An incomplete form of dRTA, without obvious blood chemistry changes, is common among stone formers who cannot acidify their urine below pH 5.3 during a formal acid-loading test.
Medications: Carbonic anhydrase inhibitors, including topiramate (used for migraines and seizures), acetazolamide, and zonisamide, raise urine pH and lower citrate. They create a biochemical picture that mimics dRTA. If you take any of these, monitoring your supersaturation is important.
Hormonal and structural conditions: Primary hyperparathyroidism drives up calcium excretion and was found in 17% of brushite stone formers. Medullary sponge kidney, a structural abnormality of the kidney's collecting ducts, is another recognized association. Autoimmune diseases such as Sjögren syndrome and systemic lupus erythematosus can damage the kidney's acid-secreting cells, leading to dRTA.
Not all calcium phosphate stones are the same. The two crystalline forms have different metabolic profiles, and knowing which type you form can guide treatment.
| Feature | Apatite (Hydroxyapatite) | Brushite |
|---|---|---|
| Frequency among CaP stones | 88% | 12% |
| Predominant sex | Women (80%) | More even distribution |
| Average urine calcium | 205 mg/day | 330 mg/day |
| Average CaP supersaturation | 1.42 | 2.58 |
| Rate of low citrate | 55% (highest of any stone type) | Lower |
| Primary hyperparathyroidism | Less common | 17% |
| Hypercalciuria | Present but less dominant | 80% of formers |
Sources: Moreira et al.; Brinkman et al.; Pak et al.
What this means for you: if your stone analysis shows brushite, the priority is aggressively lowering urine calcium, because brushite formers excrete far more calcium and carry higher supersaturation. If your stone is apatite, restoring citrate and addressing alkaline pH are likely the most productive targets.
Because calcium phosphate supersaturation is a composite value driven by multiple urinary factors, interventions target those individual components. The goal is to bring supersaturation below 1 and keep it there.
Fluid intake: Increasing urine volume dilutes all the dissolved solutes, lowering supersaturation directly. This is the simplest and most universally applicable intervention. Treatment guidelines recommend targeting urine output of at least 2.5 liters per day.
Thiazide diuretics: These prescription medications reduce the amount of calcium your kidneys excrete into the urine. By lowering urine calcium, they reduce supersaturation. Thiazides are particularly important for brushite formers with marked hypercalciuria and can also make citrate supplementation safer by offsetting the pH rise.
Potassium citrate (used with caution): Citrate supplementation raises urine citrate, which inhibits crystal formation. However, because it also raises urine pH, it can paradoxically worsen calcium phosphate supersaturation. After starting potassium citrate, you should have your urine pH, citrate, and supersaturation rechecked. If citrate does not rise and supersaturation worsens, the medication is unlikely to help. If supersaturation rises and stays consistently above 1, potassium chloride should be substituted.
Alkali therapy for dRTA: If you have distal renal tubular acidosis, potassium citrate is indicated to correct chronic acid retention, but the accompanying rise in urine pH may require adding a thiazide to control calcium excretion.
Medication review: If you take topiramate, acetazolamide, or zonisamide, discuss alternatives with your prescriber. These medications raise urine pH and lower citrate, directly increasing calcium phosphate supersaturation.